Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Ligand and SQ Innovation announced a long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide.
read more
Friday, December 23, 2016
Ligand Pharmaceuticals has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of trametinib, a kinase inhibitor currently indicated as a single agent...
read more
Ligand will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1 antibody GLS-010 to Arcus Biosciences.
read more
Ligand Pharmaceuticals has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics.
read more
Wednesday, February 15, 2017
Ligand Pharmaceuticals has announced the appointment of Christel Iffland, Ph.D. as a Vice President of Antibody Technologies.
read more
Ligand Pharmaceuticals announced the appointment of Nancy Ryan Gray, Ph.D. to the company’s Board of Directors.
read more
Wednesday, September 30, 2015
Ligand Pharmaceuticals has expanded its global license and supply agreements with SAGE Therapeutics to now also cover the use of Captisol® in the development and commercialization of SAGE-689.
read more
Ligand Pharmaceuticals has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals.
read more
Ligand Pharmaceuticals has entered into a worldwide license agreement with Gilead Sciences, Inc. Under the license, Gilead will be able to use the OmniRat®, OmniMouse® and OmniFlic® platforms to discover fully human mono- and bispecific antibodies to...
read more
Ligand Pharmaceuticals has entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology.
read more
Thursday, January 11, 2018
Ligand Pharmaceuticals has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals.
read more
Ligand has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand’s Captisol technology in the formulation of AMG 330.
read more
Ligand Pharmaceuticals has entered into an agreement with venBio Partners which permits venBio’s portfolio companies to enter into a pre-agreed worldwide OmniAb platform license agreement.
read more
Monday, November 26, 2018
Ligand has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ.
read more
Ligand Pharmaceuticals Incorporated has announcedthe signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on ...
read more